Aldeyra rises as eye disease therapy meets late-stage study goal

Aldeyra Therapeutics

08/08/2024 13:08

** Shares of drug developer Aldeyra Therapeutics  ALDX.O 
rise 10.4% to $3.60 premarket 
    ** Co says its experimental therapy to treat dry eye disease
met the main goal of a late-stage study
    ** Dry eye disease affects the layers of tears that cover
the cornea causing symptoms like burning, itching and blurred
vision 
    ** Co says the therapy reproxalap was statistically superior
in reducing the symptom of ocular discomfort in patients 
    ** Trial was designed to satisfy the U.S. FDA's marketing
application resubmission requirement - co 
    ** No safety signals were observed in the clinical trial,
and reproxalap was well tolerated- ALDX 
    ** The FDA last year rejected the therapy as it did not
demonstrate efficacy in treating symptoms of the disease
    ** Up to last close, stock down 7.1% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))